癌症治疗后疼痛是最持久的症状之一。中枢神经系统可能错误地停留在报警阶段，改变了患有癌症的患者的疼痛体验。疼痛神经科学教育（PNE）与多模式方法可能对这些患者有益。该方案旨在确定在乳腺癌（BC）患者中，以多模式康复（MR）计划为补充的PNE工具对疼痛、身体功能和生活质量的有效性。将进行为期8个星期的双盲随机对照试验，包括72名有持续疼痛的BC患者，随机分为三组：PNE计划+MR计划、传统生物医学信息+MR计划和对照组。PNE计划将包括参与者通过移动应用程序学习的教育内容，MR计划将包括同时进行的运动计划和手动疗法。主要结果将通过视觉模拟量表评估感知疼痛，次要结果与疼痛、身体功能和生活质量有关。所有结果将在基线、干预结束时和干预结束后6个月进行评估。该研究方案可能有助于BC患者缓解持续疼痛、改善生活质量，并提供更适应性的疼痛应对策略。该方案可能提出一个行动指南，以实施不同的综合方法治疗后遗症。此治疗选择可提供给这个患者群体，并且由于其成本低，可以在医疗保健系统中轻松实施。ClinicalTrials.gov，NCT04877860。（2022年2月18日）。版权所有：©2023 Fernández-Gualda等人。本文为开放获取文章，根据知识共享署名许可协议，允许任何媒体以任何形式自由使用、分发和重制，前提是原始作者和来源得到信任。

Pain is one of the most persistent symptoms after cancer treatment. The central nervous system can erroneously stay in its alarm phase, altering the pain experience of patients who have cancer. Pain neuroscience education (PNE) with multimodal approaches may benefit these patients.This protocol aims to determine the effectiveness of a PNE tool on pain, physical function and quality of life, as a supplement to a multimodal rehabilitation (MR) program in patients who had breast cancer (BC).An 8-week double-blinded randomized controlled trial will be conducted, including 72 participants who had BC and who have persistent pain, randomized into three groups: PNE program + MR program, traditional biomedical information + MR program and control group. The PNE program will include educational content that participants will learn through a mobile app and the MR program will include a concurrent exercise program and manual therapy. The primary outcome will be the perceived pain assessed using the Visual Analogue Scale and secondary outcomes are others related to pain, physical function and quality of life. All outcomes will be evaluated at baseline, at the end of the intervention and 6 months after the end of intervention.The proposed study may help BC patients with persistent pain improve their pain experience, quality of life and provide for more adaptive pain-coping strategies. This protocol could propose an action guide to implement different integral approaches for the treatment of sequelae. This treatment option could be offered to this patient profile and it could be easily implemented in the healthcare systems due to its low costs.ClinicalTrials.gov, NCT04877860. (February18, 2022).Copyright: © 2023 Fernández-Gualda et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.